αB-crystallin is a useful marker for triple negative and basal breast cancers

Histopathology

Volumn 61, Issue 3, 2012, Pages 378-386

  Tsang, Julia Y S ^a   Lai, Michael W H ^a   Wong, Ken H Y ^a   Chan, Siu Ki ^b   Lam, Christopher C F ^a   Tsang, Alex K H ^c   Yu, Alex M C ^a   Tan, Puay Hoon ^d   Tse, Gary M ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b KWONG WAH HOSPITAL   (Hong Kong)

^c YAN CHAI HOSPITAL   (Hong Kong)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

crystallin; Basal like breast cancer; Immunohistochemistry

Indexed keywords

ALPHA CRYSTALLIN; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER PATIENT; CANCER SIZE; CANCER TISSUE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; TISSUE SECTION; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-CRYSTALLIN B CHAIN; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84865394082     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04234.x     Document Type: Article

References (24)

1. Cheang MC, van de Rijn M, Nielsen TO. Gene expression profiling of breast cancer. Annu. Rev. Pathol. 2008; 3; 67-97.
2. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 2001; 98; 10869-10874.
3. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 2007; 13; 4429-4434.
4. Badve S, Dabbs DJ, Schnitt SJ et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod. Pathol. 2011; 24; 157-167.
5. Bertucci F, Finetti P, Cervera N et al. How basal are triple-negative breast cancers? Int. J. Cancer 2008; 123; 236-240.
6. Wang X, Chao L, Ma G et al. Increased expression of osteopontin in patients with triple-negative breast cancer. Eur. J. Clin. Invest. 2008; 38; 438-446.
7. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004; 10; 5367-5374.
8. Elsheikh SE, Green AR, Rakha EA et al. Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br. J. Cancer 2008; 99; 327-334.
9. Livasy CA, Karaca G, Nanda R et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol. 2006; 19; 264-271.
10. Arrigo AP, Simon S, Gibert B et al. Hsp27 (HspB1) and alphaB-crystallin (HspB5) as therapeutic targets. FEBS Lett. 2007; 581; 3665-3674.
11. Aoyama A, Steiger RH, Frohli E et al. Expression of alpha B-crystallin in human brain tumors. Int. J. Cancer 1993; 55; 760-764.
12. Pinder SE, Balsitis M, Ellis IO, Landon M, Mayer RJ, Lowe J. The expression of alpha B-crystallin in epithelial tumours: a useful tumour marker? J. Pathol. 1994; 174; 209-215.
13. Chelouche-Lev D, Kluger HM, Berger AJ, Rimm DL, Price JE. AlphaB-crystallin as a marker of lymph node involvement in breast carcinoma. Cancer 2004; 100; 2543-2548.
14. Moyano JV, Evans JR, Chen F et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J. Clin. Invest. 2006; 116; 261-270.
15. Ivanov O, Chen F, Wiley EL et al. AlphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res. Treat. 2008; 111; 411-417.
16. Sitterding SM, Wiseman WR, Schiller CL et al. AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas. Ann. Diagn. Pathol. 2008; 12; 33-40.
17. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403-410.
18. Tavassoli FA, Devilee P eds. World Health Organization classification of tumors. Pathology and genetics of tumors of the breast and female genital organs. London: IARC Press, 2003.
19. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007; 25; 118-145.
20. Reis-Filho JS, Milanezi F, Steele D et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006; 49; 10-21.
21. Weigelt B, Horlings HM, Kreike B et al. Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol. 2008; 216; 141-150.
22. Chan SK, Lui PC, Tan PH et al. Increased alpha-B-crystallin expression in mammary metaplastic carcinomas. Histopathology 2011; 59; 247-255.
23. Harris LN, You F, Schnitt SJ et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin. Cancer Res. 2007; 13; 1198-1207.
24. Kamada M, So A, Muramaki M, Rocchi P, Beraldi E, Gleave M. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol. Cancer Ther. 2007; 6; 299-308.